Baxter International: The Vantive Transition Complicates Margin Recovery

Narek Hovhannisyan 568 Followers Follow Summary Baxter International is rated Hold, with a $25 target price and limited 2.6% upside, reflecting muted near-term margin recovery. Revenue growth is supported by Advanced Surgery and compounding, but infusion solutions face structural headwinds, and Novum IQ LVP supply issues persist. Margins lag revenue growth; cost reductions and inventory normalization may help, but transition expenses and debt reduction remain priorities through 2027. BAX trades at a discount to sector and historical multiples but is justified by weak infusion recovery, product limitations, and ongoing expense uncertainty. PR-PhotoDesign/iStock Editorial via Getty Images Investment Thesis This is my third article about the company—both times before , I chose a Hold rating, and this time I’m maintaining the same rating for Baxter’s ( BAX ) shares. Yes, the company’s revenue This article was written by Narek Hovhannisyan 568 Followers Follow Hi there! I’m Narek, and I’ve been in the investment world for over six years. I started out as an equity analyst at European banks, digging into reports and learning how to spot value in the markets. I’ve worked across sectors — from telecom to industry — and found that behind every financial statement is a real story. I studied in Belgium — did my bachelor’s in Antwerp, master’s at KU Leuven, and later completed an MBA in Finance at Vlerick. That journey gave me both theory and hands-on skills. Now I’m building my own investment project focused on the CIS region. I’m passionate about applying Western analytical tools to uncover hidden value in emerging markets. If you enjoy deep, fundamentals-driven research and digging beneath the surface of a company — glad to have you on board! Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.